Anixa's Ovarian Cancer CAR-T Therapy Trial Data to Be Presented at SGO Annual Meeting
Event summary
- Anixa Biosciences' Phase 1 trial for lira-cel, its CAR-T therapy targeting recurrent ovarian cancer, will be presented by Dr. Robert Wenham at the SGO Annual Meeting on April 10–13, 2026.
- The trial (NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.
- Lira-cel uses a novel CER-T technology targeting the follicle-stimulating hormone receptor (FSHR), selectively expressed on ovarian cells and tumor vasculature.
- Anixa collaborates with Moffitt Cancer Center on the trial and with Cleveland Clinic on its vaccine portfolio.
The big picture
Anixa's presentation at the SGO meeting highlights the growing focus on CAR-T therapies for solid tumors, an area where traditional CAR-T treatments have struggled. The company's collaboration with Moffitt Cancer Center underscores the strategic importance of academic partnerships in advancing novel immunotherapies. Success in this trial could position Anixa as a key player in ovarian cancer treatment, a market with significant unmet needs.
What we're watching
- Trial Progress
- The presentation's findings will indicate whether lira-cel's novel CER-T approach shows early efficacy in recurrent ovarian cancer.
- Regulatory Pathway
- The pace at which Anixa advances lira-cel through Phase 1 will determine its timeline for potential regulatory approval.
- Competitive Positioning
- How lira-cel's FSHR-targeting mechanism differentiates it from other CAR-T therapies in development for ovarian cancer.
Related topics